Picard Medical Files S-1/A Amendment 3, Nears IPO Launch
Ticker: PMI · Form: S-1/A · Filed: May 23, 2025 · CIK: 2030617
Sentiment: neutral
Topics: S-1/A, IPO, Medical Devices, Emerging Growth Company, SEC Filing, Healthcare, Tucson AZ
Related Tickers: PMI
TL;DR
**Picard Medical is inching closer to its IPO, but this S-1/A is mostly administrative, so don't expect any major financial revelations yet.**
AI Summary
Picard Medical, Inc. (PMI) filed an S-1/A on May 23, 2025, as Amendment No. 3 to its initial S-1 registration statement, indicating its intent to commence a public sale of securities as soon as practicable. The company, classified as a Smaller Reporting Company and an Emerging Growth Company, operates in the Surgical & Medical Instruments & Apparatus sector (SIC 3841). While specific revenue and net income figures are not detailed in this amendment, the filing confirms its corporate structure in Delaware and its principal executive offices at 1992 E Silverlake, Tucson, AZ. The amendment primarily updates legal and administrative details, including the appointment of Patrick NJ Schnegelsberg as CEO and agent for service, and lists legal counsel from Winston & Strawn LLP and Sheppard, Mullin, Richter & Hampton LLP. The lack of updated financial specifics in this amendment suggests the company is still in the preparatory stages for its IPO, focusing on regulatory compliance and legal structuring. The filing does not provide new information on key business changes, risks, or strategic outlook beyond its intention to go public.
Why It Matters
This S-1/A filing signals Picard Medical's continued progress towards its initial public offering, offering a potential new investment opportunity in the medical instruments sector. For investors, it means a new player is entering the public market, potentially diversifying portfolios in a growing industry. Employees could see increased equity value and growth opportunities as the company expands. Customers might benefit from increased innovation and product availability driven by public funding. In the competitive landscape, PMI's entry could intensify competition among existing medical device manufacturers, potentially driving down costs or accelerating technological advancements.
Risk Assessment
Risk Level: medium — The risk level is medium because, as an Emerging Growth Company and Smaller Reporting Company, Picard Medical will have fewer disclosure requirements, potentially limiting investor insight into its operations and financial health. The S-1/A itself does not contain updated financial data, which means investors are still operating with incomplete information regarding the company's current performance and specific risks. The lack of detailed financial updates in this amendment suggests that significant financial risks or opportunities are not being disclosed at this stage, requiring further due diligence.
Analyst Insight
Investors should monitor subsequent filings for detailed financial statements and business descriptions to assess Picard Medical's valuation and growth prospects. Given the administrative nature of this S-1/A, it's premature to make investment decisions; wait for the final prospectus with pricing and comprehensive financial data.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Patrick NJ Schnegelsberg | Chief Executive Officer |
Key Numbers
- 333-286295 — Registration No. (SEC file number for the S-1 registration statement)
- 3841 — SIC Code (Primary Standard Industrial Classification for Surgical & Medical Instruments & Apparatus)
- 2025-05-23 — Filing Date (Date S-1/A Amendment No. 3 was filed)
- 1992 E Silverlake — Business Address (Principal executive offices of Picard Medical, Inc.)
- 520-545-1234 — Business Phone (Telephone number for Picard Medical, Inc.)
Key Players & Entities
- Picard Medical, Inc. (company) — Registrant for S-1/A filing
- Patrick NJ Schnegelsberg (person) — Chief Executive Officer and Agent for Service
- Winston & Strawn LLP (company) — Legal counsel for the registrant
- Sheppard, Mullin, Richter & Hampton LLP (company) — Legal counsel for the registrant
- U.S. Securities and Exchange Commission (regulator) — Regulatory body overseeing the filing
- Michael J. Blankenship (person) — Attorney at Winston & Strawn LLP
- Beniamin D. Smolij (person) — Attorney at Winston & Strawn LLP
- Richard A. Friedman, Esq. (person) — Attorney at Sheppard, Mullin, Richter & Hampton LLP
- Sean F. Reid, Esq. (person) — Attorney at Sheppard, Mullin, Richter & Hampton LLP
- Emily Mastoloni Esq. (person) — Attorney at Sheppard, Mullin, Richter & Hampton LLP
FAQ
What is the purpose of Picard Medical's S-1/A Amendment No. 3 filing?
Picard Medical's S-1/A Amendment No. 3, filed on May 23, 2025, serves to update and amend its initial S-1 registration statement, primarily addressing administrative and legal details in preparation for its proposed public sale of securities. It confirms the company's intent to commence the sale as soon as practicable after the effective date.
Who is the CEO of Picard Medical, Inc. as per the S-1/A filing?
According to the S-1/A filing, Patrick NJ Schnegelsberg is the Chief Executive Officer of Picard Medical, Inc. He is also designated as the agent for service for the company.
What industry does Picard Medical, Inc. operate in?
Picard Medical, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as indicated by its Primary Standard Industrial Classification (SIC) Number 3841.
Is Picard Medical, Inc. considered an Emerging Growth Company?
Yes, Picard Medical, Inc. has indicated by check mark in the S-1/A filing that it is an Emerging Growth Company, which allows it to take advantage of certain reduced reporting requirements.
What is the business address of Picard Medical, Inc.?
The business address for Picard Medical, Inc. is 1992 E Silverlake, Tucson, AZ, 85713, with a business phone number of (520) 545-1234.
Which law firms are representing Picard Medical, Inc. in this S-1/A filing?
Picard Medical, Inc. is being represented by Winston & Strawn LLP, with attorneys Michael J. Blankenship and Beniamin D. Smolij, and Sheppard, Mullin, Richter & Hampton LLP, with attorneys Richard A. Friedman, Sean F. Reid, and Emily Mastoloni Esq.
What is the significance of Picard Medical being a Smaller Reporting Company?
As a Smaller Reporting Company, Picard Medical, Inc. is subject to scaled disclosure requirements, which can result in less detailed financial and operational information being available to investors compared to larger public companies. This status is indicated by a check mark in the S-1/A filing.
When does Picard Medical, Inc. anticipate commencing its proposed sale to the public?
Picard Medical, Inc. anticipates commencing its proposed sale to the public as soon as practicable after the effective date of this Registration Statement, as stated in the S-1/A filing.
Does the S-1/A Amendment No. 3 for Picard Medical include updated financial figures?
No, the S-1/A Amendment No. 3 for Picard Medical, Inc. primarily focuses on administrative and legal updates and does not include new or updated financial figures such as revenue or net income. Investors should look for subsequent filings for detailed financial information.
What is the SEC file number for Picard Medical's S-1 registration statement?
The SEC file number for Picard Medical, Inc.'s S-1 registration statement is 333-286295, as stated on the cover page of the S-1/A Amendment No. 3.
Industry Context
Picard Medical operates in the Surgical & Medical Instruments & Apparatus sector (SIC 3841). This industry is characterized by innovation, stringent regulatory oversight (e.g., FDA approvals), and a competitive landscape with both large established players and smaller specialized firms. Trends include advancements in minimally invasive technologies, digital health integration, and increasing demand driven by an aging global population and advancements in healthcare.
Regulatory Implications
As a medical device company, Picard Medical is subject to rigorous regulatory scrutiny, primarily from the FDA. Compliance with quality system regulations, pre-market approval processes, and post-market surveillance are critical. The S-1/A filing itself is a regulatory requirement for its IPO, demanding transparency on business operations, risks, and financials.
What Investors Should Do
- Monitor for updated financial disclosures.
- Evaluate the competitive positioning within the medical instruments sector.
- Assess management team's experience and track record.
Key Dates
- 2025-05-23: Filing of S-1/A Amendment No. 3 — Indicates the company is actively progressing towards its IPO, focusing on regulatory and administrative updates.
Glossary
- S-1/A
- An amendment to an S-1 registration statement filed with the SEC, used to update or correct information before an initial public offering (IPO). (This is the primary filing document for Picard Medical's IPO, indicating its intent to go public and providing necessary disclosures.)
- Smaller Reporting Company
- A classification by the SEC for companies meeting certain revenue and public float thresholds, allowing for scaled disclosure requirements. (Picard Medical qualifies as a Smaller Reporting Company, suggesting it may have less extensive financial reporting obligations in its IPO.)
- Emerging Growth Company
- A company with less than $1.235 billion in annual gross revenue that has gone public within the last five years, eligible for certain regulatory accommodations. (Picard Medical's status as an Emerging Growth Company allows it to benefit from extended transition periods for new accounting standards, potentially simplifying initial compliance.)
- SIC Code
- Standard Industrial Classification code used to categorize businesses by industry. (Picard Medical's SIC code 3841 (Surgical & Medical Instruments & Apparatus) places it within a specific sector, allowing for industry-specific comparisons and analysis.)
- Agent for Service
- An individual or entity designated to receive legal documents on behalf of a company. (The appointment of Patrick NJ Schnegelsberg as the agent for service highlights a key legal requirement for public companies and indicates operational readiness.)
Year-Over-Year Comparison
This filing is Amendment No. 3 to the S-1 registration statement. As it primarily addresses legal and administrative updates, including the appointment of the CEO and agent for service, it does not provide comparative financial metrics against prior periods. The lack of updated financial data means a direct comparison of revenue growth, margin changes, or other key financial highlights to previous filings is not possible at this stage.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on May 23, 2025 by Patrick NJ Schnegelsberg regarding Picard Medical, Inc. (PMI).